RATIONALE: Permissive hypercapnia is established in lung injury management. Therapeutic hypercapnia causes benefit or harm, depending on the context. Ventilator-associated lung injury has a wide spectrum of candidate mechanisms, affording multiple opportunities for intervention such as hypercapnia to exert benefit or harm. OBJECTIVES: To confirm (1) that hypercapnia attenuates in vivo ventilator-induced lung injury (VILI); (2) biological plausibility of such protection (e.g., dose-response, time series, inflammatory profile); and (3) that the associated biochemical events are consistently beneficial. METHODS: A mouse model of VILI was established in vivo. Injurious ventilation was established, hypercapnia applied and markers of inflammation measured. MEASUREMENTS: Lung injury was quantified by gas exchange, elastance, microvascular leak, histology and levels of cytokines and eicosanoids, cyclooxygenase and tissue nitrotyrosine. MAIN RESULTS: Injurious ventilation caused significant lung injury (mechanics, microvascular leak, histology) and release of inflammatory cytokines, chemokines and eicosanoids. Hypercapnia attenuated these responses, with dose-response and time-dependent effects. No adverse effects of hypercapnia were observed in controls. Hypercapnia suppressed the transcription (mRNA) and translation (protein) of the major inducible prostanoid-generating enzyme (COX-2), but the effects on the downstream eicosanoids were modest. However, hypercapnia significantly increased lung tissue nitrotyrosine-at PaCO(2) levels that were protective. CONCLUSIONS: Hypercapnia provided consistent and biologically plausible in vivo protection against VILI, but elevated lung tissue levels of nitro-tyrosine as previously described in sepsis. Clinicians and those designing clinical trials need to be aware of the potential for detrimental effects when using hypercapnia in order to balance benefits versus harm with this approach.
RATIONALE: Permissive hypercapnia is established in lung injury management. Therapeutic hypercapnia causes benefit or harm, depending on the context. Ventilator-associated lung injury has a wide spectrum of candidate mechanisms, affording multiple opportunities for intervention such as hypercapnia to exert benefit or harm. OBJECTIVES: To confirm (1) that hypercapnia attenuates in vivo ventilator-induced lung injury (VILI); (2) biological plausibility of such protection (e.g., dose-response, time series, inflammatory profile); and (3) that the associated biochemical events are consistently beneficial. METHODS: A mouse model of VILI was established in vivo. Injurious ventilation was established, hypercapnia applied and markers of inflammation measured. MEASUREMENTS: Lung injury was quantified by gas exchange, elastance, microvascular leak, histology and levels of cytokines and eicosanoids, cyclooxygenase and tissue nitrotyrosine. MAIN RESULTS: Injurious ventilation caused significant lung injury (mechanics, microvascular leak, histology) and release of inflammatory cytokines, chemokines and eicosanoids. Hypercapnia attenuated these responses, with dose-response and time-dependent effects. No adverse effects of hypercapnia were observed in controls. Hypercapnia suppressed the transcription (mRNA) and translation (protein) of the major inducible prostanoid-generating enzyme (COX-2), but the effects on the downstream eicosanoids were modest. However, hypercapnia significantly increased lung tissue nitrotyrosine-at PaCO(2) levels that were protective. CONCLUSIONS:Hypercapnia provided consistent and biologically plausible in vivo protection against VILI, but elevated lung tissue levels of nitro-tyrosine as previously described in sepsis. Clinicians and those designing clinical trials need to be aware of the potential for detrimental effects when using hypercapnia in order to balance benefits versus harm with this approach.
Authors: J G Laffey; M Tanaka; D Engelberts; X Luo; S Yuan; A K Tanswell; M Post; T Lindsay; B P Kavanagh Journal: Am J Respir Crit Care Med Date: 2000-12 Impact factor: 21.405
Authors: Ian B Copland; Denis Reynaud; Cecil Pace-Asciak; Martin Post Journal: Am J Physiol Lung Cell Mol Physiol Date: 2006-04-07 Impact factor: 5.464
Authors: Scott E Sinclair; David A Kregenow; Wayne J E Lamm; Ian R Starr; Emil Y Chi; Michael P Hlastala Journal: Am J Respir Crit Care Med Date: 2002-08-01 Impact factor: 21.405
Authors: John G Laffey; Robert P Jankov; Doreen Engelberts; A Keith Tanswell; Martin Post; Thomas Lindsay; J Brendan Mullen; Alex Romaschin; Derek Stephens; Colin McKerlie; Brian P Kavanagh Journal: Am J Respir Crit Care Med Date: 2003-12-01 Impact factor: 21.405
Authors: Kathryn M Oliver; Colin R Lenihan; Ulrike Bruning; Alex Cheong; John G Laffey; Paul McLoughlin; Cormac T Taylor; Eoin P Cummins Journal: J Biol Chem Date: 2012-03-06 Impact factor: 5.157
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2011-01-04 Impact factor: 17.440
Authors: Thomas Bein; Steffen Weber-Carstens; Anton Goldmann; Thomas Müller; Thomas Staudinger; Jörg Brederlau; Ralf Muellenbach; Rolf Dembinski; Bernhard M Graf; Marlene Wewalka; Alois Philipp; Klaus-Dieter Wernecke; Matthias Lubnow; Arthur S Slutsky Journal: Intensive Care Med Date: 2013-01-10 Impact factor: 17.440